Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines.
Saved in:
| Title: | Phase II study of trifluridine/tipiracil in metastatic breast cancers with or without prior exposure to fluoropyrimidines. |
|---|---|
| Authors: | Lim JSJ; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore; Experimental Therapeutics Programme, Cancer Science Institute, Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore., Ow SGW; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Wong ALA; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore; Experimental Therapeutics Programme, Cancer Science Institute, Singapore, Singapore., Lee MXW; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Chan GHJ; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Low JL; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Sundar R; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore., Choo JRE; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Chong WQ; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Ang YLE; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore., Tai BC; Saw Swee Hock School of Public Health, National University Singapore, Singapore., Lee SC; Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore; Experimental Therapeutics Programme, Cancer Science Institute, Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore. Electronic address: csilsc@nus.edu.sg. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 193, pp. 113311. Date of Electronic Publication: 2023 Aug 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
